Meeting
2023 ASCO Annual Meeting
Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.
Authors
Jun Guo
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
Jun Guo , Chuanliang Cui , Bin Lian , Xuan Wang , Zhihong Chi , Lu Si , Xinan Sheng , Yan Kong , Lili Mao , Bixia Tang , Xue Bai , Xieqiao Yan , Siming Li , Li Zhou , Juan Li , Yue Yang , Hui Tian , Caili Li , Rong Duan , Huayan Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04871334
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9530)
DOI
10.1200/JCO.2023.41.16_suppl.9530
Abstract #
9530
Poster Bd #
293
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
First Author: Georgina V. Long
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long
Poster
2019 ASCO Annual Meeting
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
First Author: Georgina V. Long
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
First Author: Reinhard Dummer